[P] Poster Discussion & Discussion Meeting | The 30th Annual Meeting of the Japanese Society for Vaccinology/The 67th Annual Meeting of the Japanese Society of Clinical Virology

The 30th Annual Meeting of the Japanese Society for Vaccinology/The 67th Annual Meeting of the Japanese Society of Clinical Virology

Session Details

Poster Discussion

[P]Poster Discussion & Discussion Meeting

Sat. Sep 26, 2026 5:30 PM - 6:20 PM JST
Sat. Sep 26, 2026 8:30 AM - 9:20 AM UTC

Poster Section(2F Snow Hall B)

[P-01]FilmArray^®呼吸器パネル2.1検査で検出されたHuman Rhinovirus/Enterovirusのウイルス種同定と臨床症状との関連

*Kunihiro Oba^1,2, Atsushi Kaida³, Kazuhiro Horiba⁴, Yumani Kuba⁵, Nobuhiro Takemae⁵, Tsutomu Kageyama⁵ (1. Department of Pediatrics, Showa General Hospital, 2. Department of Infection Control and Prevention, Showa General Hospital, 3. Virology section, Osaka Institute of Public Health, 4. Laboratory of Microbial Genomics, Pathogen Genomics Center, National Institute of Infectious Diseases, Japan Institute for Health Security, 5. Department of Diagnostic Testing and Technology Research, National Institute of Infectious Diseases, Japan Institute for Health Security)

[P-02]インフルエンザA, 重症急性呼吸器症候群コロナウイルス2の共感染に伴い発症した好酸球性鋳型気管支炎の小児例

*Tsunehisa Nagamori¹, Masayuki Sato¹, Emi Ishibazawa¹, Satoru Takahashi¹ (1. Department of Pediatrics, Asahikawa Medical University)

[P-03]Effective suppression of drug-resistant CMV infection post-renal transplant with CMV immunoglobulin

*Julian Wei-Tze Tang¹, Sujata Dutta², Rehana Raza², John Black², Ibrahim Chapra², Anna Rizzello², Jorge Jesus-Silva², Dipesh Patel³, Wael Goravey¹, Daniel Pan¹, Oliver TR Toovey¹, Atul Bagul² (1. Department of Clinical Microbiology, University Hospitals of Leicester NHS Trust, Leicester, UK, 2. Department of Renal Transplant, University Hospitals of Leicester NHS Trust, Leicester, UK, 3. Department of Pharmacy, University Hospitals of Leicester NHS Trust, Leicester, UK)

[P-04]感染性胃腸炎におけるアストロウイルスおよびサポウイルスの臨床像

*Ken Sugata¹, Yusuke Aoki¹, Shigeru Suga¹, Azusa Kawaguchi², Hidetaka Nakai³, Yoshiki Kawamura⁴, Masato Itano⁴, Hiroki Miura⁵, Tomoyuki Mizukami⁶, Hideki Mori⁷ (1. Mie National Hospital, 2. Hokkado medical center, 3. Tohokawa city hospital, 4. Fujita Health Univ. Okazaki medical center, 5. Fujita Health University hospital, 6. Kumamoto medical center, 7. Nagasaki medical center)

[P-05]大学病院ワクチン外来における成人ワクチン接種率向上のための取り組み

*Hiroyuki Aiba^1,2, Rika Goto², Tomohiro Katsuta^1,2, Kunishima Hiroyuki^1,3 (1. Infectious Disease Center, St. Marianna University School of Medicine, 2. Department of Pediatrics, St. Marianna University School of Medicine, 3. Department of Infectious Diseases, St. Marianna University School of Medicine)

[P-06]静岡県予防接種センターにおけるメーリングリストを利用した行政スタッフとの予防接種情報の共有と相談内容の変化

*Takayo Shoji¹, Toshihiro Tanaka² (1. Shizuoka children's hospital General pediatrics Pediatric intectious diseases, 2. Shizuoka walfare hospital)

[P-07]乳児早期のワクチン同時接種における最適な接種順序の検討
― 接種時疼痛の観点から ―

*Hiromi Muta¹ (1. Iizuka Children's Clinic)

[P-08]妊婦に対する百日咳含有ワクチン接種の安全性：他のワクチン接種状況を考慮した検討

*Satoko Ohfuji^1,2, Ayane Kasamatsu¹, Chika Mochiduki¹, Tomoko Takeuchi¹, Yoshie Sugawara¹, Hideaki Fukuma³, Toshihiro Tanaka⁴, Kenji Okada⁵, Wakaba Fukushima^1,2 (1. Department of Public Health, Osaka Metropolitan University Graduate School of Medicine, 2. Research Center for Infectious Disease Sciences, Osaka Metropolitan University Graduate School of Medicine, 3. Fukuma Clinic Obstetrics and Gynecology, 4. Department of Pediatrics, Shizuoka Kosei Hospital, 5. Fukuoka Nursing College)

[P-09]看護学生入学時の麻疹、風疹抗体価の動向～2008年から2025年まで～

*YUKA MIHARA MIHARA¹, Mitsunobu Miyazu¹, Toshihito Nagata¹, Hitoshi Kikuchi¹ (1. Vaccinations center, Meitetsu Hospital)

[P-10]循環器内科外来患者における帯状疱疹ワクチン接種の現状

*Takenori Okada¹ (1. Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital)

[P-11]Influenza Vaccine Effectiveness in Children: Association with Lifetime Influenza Vaccination History

*Ayako Konishi¹, Saeko Morikawa², Keiko Nakata², Satoshi Hiroi², Matsuura Tomoka¹, Kyoko Kondo³, Tetsuo Kase¹, Satoko Ohfuji¹, Wakaba Fukushima¹, Japanese Monitoring Study Group on Influenza Vaccine Effectiveness⁴ (1. Department of Public Health, Osaka Metropolitan University Graduate School of Medicine, 2. Division of Microbiology, Osaka Institute of Public Health, 3. OMU Core Facilities Life Sciences Section, Osaka Metropolitan University, 4. Japanese Monitoring Study Group on Influenza Vaccine Effectiveness)

[P-12]インフルエンザワクチン接種後の抗体価にALDH2 rs671多型が及ぼす影響についての前向き観察研究

*Tatsuya Yoshihara¹, Takashi Eto², Junko Manabe¹, Yoshiko Miura¹, Hiroko Kumashiro³, Andrew Melli³, Shunji Matsuki¹, Shin Irie⁴ (1. SOUSEIKAI Fukuoka Mirai Hospital Clinical Research Center, 2. SOUSEIKAI Hakata Clinic, 3. SOUSEIKAI Clinical Research Division, Innovation and Strategic Business, Senior Manager , 4. SOUSEIKAI)

[P-13]ロタウイルスワクチン定期接種化後の腸重積症サーベイランスについて

*Miho Shibamura-Fujiogi¹, Hajime Kamiya¹, Yuichiro Yahata¹, Takeshi Tsugawa², Mitsuaki Hosoya³, Naruhiko Ishiwada⁴, Akihiko Saitoh⁵, Shigeru Suga⁶, Tetsuya Sato⁷, Sayaka Okuzono⁸, Yumiko Nakajima⁹, Yoshiaki Cho¹⁰, Motoi Suzuki¹ (1. (JIHS)Japan Institute for Health Security, National institute of infectious diseases, 2. Department of Pediatrics, Sapporo Medical University School of Medicine , 3. Department of Perinatology and Pediatrics for Regional Medical Support, Fukushima Medical University, 4. Department of Infectious Diseases, Medical Mycology Research Center, Chiba University, 5. Department of Pediatrics, Niigata University Graduate School of Medical and Dental Sciences, 6. Department of Pediatrics, National Hospital Organization Mie National Hospital, 7. Department of Pediatrics, National Hospital Organization Kochi Hospital , 8. Department of Pediatrics, Fukuoka Dental College Medical and Dental Hospital, 9. Parenting Support Division, Child Department, Nagasaki City , 10. Division of Pediatric Infectious Disease, Department of Pediatrics, Okinawa Prefectural Nanbu Medical Center and Children's Medical Center)

[P-14]Association of Gut Microbiome α-Diversity with IgA Antibody Responses after Rotavirus Vaccination in Healthy Infants

*Yuki Higashimoto¹, Masashi Hotta², Masaru Ihira³, Hiroyuki Hiramatsu⁴, Kouji Hosomi⁷, Yoshiki Kawamura^5,6, Hiroki Miura⁵, Jun-Ichi Kawada⁵, Jun Kunisawa², Tetsushi Yoshikawa⁵ (1. Department of Clinical Microbiology, Fujita Health University School of Medical Sciences, 2. Microbial Research Center for Health and Medicine, National Institutes of Biomedical Innovation, Health and Nutrition (NIBN), 3. Department of Clinical Science for Biological Monitoring, Fujita Health University School of Medical Sciences, 4. Department of Pharmacotherapeutics and informatics , Fujita Health University School of Medicine, 5. Department of Pediatrics, Fujita Health University School of Medicine, 6. Department of Pediatrics, Fujita Health University Okazaki Medical Center, 7. Graduate School of Veterinary Science, Osaka Metropolitan University)

[P-15]痘そうワクチンLC16接種者におけるMPXVに対する中和抗体価の長期動態解析

*Shiori Ueno¹, Akira Ainai¹, Akiko Sataka¹, Hidetoshi Nomoto², Kozue Takahashi², Eriko Morino³, Mugen Ujiie², Tadaki Suzuki¹ (1. Department of Infectious Disease Pathology, National Institute of Infectious Diseases, Japan Institute for Health Security, 2. Disease Control and Prevention Center, National Center for Global Health and Medicine, Japan Institute for Health Security , 3. Department of Respiratory Medicine, National Center for Global Health and Medicine; Department of International Trials, Center for Clinical Sciences Japan Institute for Health Security)

[P-16]A(H10)亜型インフルエンザワクチンのHA抗原量測定に向けたID-MS標的ペプチドの選定と評価

*Yusuke Nakai^1,2,3, Ryuichi Sugiyama², Yuichi Harada², Noriko Shimasaki², Toru Takenaga^1,2, Hideki Hasegawa², Akihide Ryo³ (1. Department of Diagnostic Testing and Technology Research, National Institute of Infectious Diseases, Japan Institute for Health Security, 2. Influenza Research Center, National Institute of Infectious Diseases, Japan Institute for Health Security, 3. Department of Bioinformatics and Integrative Omics, National Institute of Infectious Diseases, Japan Institute for Health Security)

[P-17]麻疹ウイルスNタンパク質特異的モノクローナル抗体を用いたサンドイッチELISAによる抗原検出系の構築と感度評価

*Suzuka Kikuchi^1,4, Fumio Seki², Yasuyoshi Hatayama¹, Mayuko Nishi¹, Fuminori Mizukoshi¹, Taichi Kameya^1,3, Yutaro Yamaoka³, Kei Haga⁴, Kazuhiko Katayama⁴, Noriyuki Otsuki², Akihide Ryo¹ (1. Department of Bioinformatics and Omics, National Institute of Infectious Diseases (NIID), Japan Institute for Health Security (JIHS), 2. Department of Respiratory Viruses, National Institute of Infectious Diseases (NIID), Japan Institute for Health Security (JIHS), 3. Life Science Laboratory, Technology and Development Division, Kanto Chemical Co., Inc., , 4. Laboratory of Viral Infection, Department of Infection Control and Immunology, Omura Satoshi Memorial Institute & Graduate School of Infection Control Sciences, Kitasato University)

[P-18]ARIサーベイランス陰性検体におけるヒトパルボウイルスB19の検出

*Akeno Tsuneki Tokunaga¹, Yuki Taira¹, Rieko Kaji¹, Ryohei Nomoto¹, Ai Mori¹ (1. Kobe Institute of Health)

[P-19]急性出血性結膜炎疑い検体に対するマルチプレックスqPCR法の開発

*Kotoha Yoshida¹, Shunsuke Yazawa¹, Junichi Kanatani², Kazunori Oishi², Hideki Tani¹ (1. Department of Virology TOYAMA INSTITUTE OF HEALTH, 2. Department of Bacteriology TOYAMA INSTITUTE OF HEALTH)

[P-20]小児感染性胃腸炎のFilmArray 消化管パネルによる原因微生物解析

*Masato Itano¹, YOSHIKI KAWAMURA¹, NATSUKI HATAKAWA¹, KATSUYUKI YOKOI¹, YOTARO KONDO², HIROKI MIURA², Ken Sugata³, JUNICHI KAWADA² (1. Department of Pediatrics, Fujita Health University Okazaki Medical Center, 2. Department of Pediatrics, Fujita Health University School of Medicine, 3. National Hospital Organization Mie National Hospital)

[P-21]Determinants of Vaccine Recommendation Behaviors Among Physicians in Japan: A Cross-Sectional Study Using the 5C Model

*Kajila Sovi¹, Mizue Kanai¹, Elijah Deku-Mwin Kuurdor¹, Shingo Mitsushima¹, Hajime Kamiya¹ (1. Mie University Department of Public Health, Occupational Medicine and Applied Epidemiology)

[P-22]二次利用データを用いた小児ワクチン安全性評価に関する研究

*Wataru Mimura¹, Taku Chikamochi¹, Chieko Ishiguro¹, Michiko Toizumi², Haruka Haruka³, Futoshi Oda⁴, Megumi Maeda⁴, Haruhisa Fukuda⁴ (1. Japan Institute for Health Security, 2. Nagasaki University, 3. Department of Respiratory Infections,Institute of Tropical Medicine,Nagasaki University, 4. Kyushu University)

[P-23]Prevalence and socioeconomic inequalities in acute respiratory infections among children under five in Indonesia

*Tri Bayu Purnama¹, Keita Wagatsuma¹, Reiko Saito¹, Narumi Matsuno¹, Tsutomu Tamura¹, Hisami Watanabe¹ (1. Division of International Health Graduate School of Medical and Dental Sciences Niigata University)

[P-24]ARI病原体サーベイランスにおける原因不明検体の病原体解明に関する研究

*Shunsuke Yazawa¹, Sara Taniguchi¹, Takahisa Shimada¹, Kazuhiro Horiba², Junichi Kanatani³, Kazunori oishi³, Hideki Tani¹ (1. Department of Virology, Toyama Institute of Health, 2. Pathogen Genomics Center, National Institute of Infectious Diseases, Japan., 3. Department of Bacteriology, Toyama Institute of Health)

[P-25]2025年度に愛知県で急性呼吸器感染症から検出されたウイルス

*Yoshihiro Yasui¹, Natsumi Ida¹, Yuho Yamada¹, Masaki Sassa¹, Tatsuya Hirayama¹, Naoki Kamiya¹, Yumi Morisugi¹, Yuuki Suwa¹, Mako Ito¹, Kuniko Ishida¹, Emi Hirose¹ (1. Aichi Prefectural Institute of Public Health)

[P-26]呼吸器感染症ワクチンの臨床的・疫学的有効性評価プラットフォーム形成検討

*Takeshi Arashiro^1,2,3, Shinji Watanabe¹, Hideki Hasegawa¹, Tadaki Suzuki^1,2 (1. National Institute of Infectious Diseases, Japan Institute for Health Security, 2. Chiba University Graduate School of Medicine, 3. Keio University School of Medicine)

[P-27]COVID-19パンデミック前後における高齢者インフルエンザワクチン接種プログラムの周辺因果効果推定値の方向逆転：連結行政データを用いた住民ベースのコホート研究

*Ayu Kasamatsu^1,6, Daisuke Yoneoka⁶, Yuichiro Yahata^2,3, Tanaka Kaori⁷, Hajime Kamiya^1,4, Wakaba Fukushima⁵ (1. Center for Infectious Disease Epidemiology, National Institute of Infectious Diseases, Japan Institute for Health Security, 2. Center for Public Health Action in Applied Epidemiology, National Institute of Infectious Diseases, Japan Institute for Health Security, 3. Department of Environmental Health, National Institute for Public Health, 4. Department of Public Health, Occupational Medicine, and Applied Epidemiology, Graduate School of Medicine, Mie University, 5. Department of Public Health, Graduate School of Medicine, Osaka Metropolitan University, 6. Department of Epidemiology, National Institute of Infectious Diseases, Japan Institute for Health Security, 7. Department of Immunization Research, National Institute of Infectious Diseases, Japan Institute for Health Security)

[P-28]COVID-19パンデミック前後高齢者インフルエンザワクチン接種関連因子の変化と接種率推移の背景構造：2017/18–2024/25シーズンの検討

*Ayu Kasamatsu^1,6, Daisuke Kasamatsu Yoneoka⁶, Yuichiro Yahata^2,3, Kaori Tanaka⁷, Hajime Kamiya^1,4, Wakaba Fukushima⁵ (1. Center for Infectious Disease Epidemiology, National Institute of Infectious Diseases, Japan Institute for Health Security, 2. Center for Public Health Action in Applied Epidemiology, National Institute of Infectious Diseases, Japan Institute for Health Security, 3. Department of Environmental Health, National Institute for Public Health, 4. Department of Public Health, Occupational Medicine, and Applied Epidemiology, Graduate School of Medicine, Mie University, 5. Department of Public Health, Graduate School of Medicine, Osaka Metropolitan University, 6. Department of Epidemiology, National Institute of Infectious Diseases, Japan Institute for Health Security, 7. Department of Immunization Research, National Institute of Infectious Diseases, Japan Institute for Health Security)

[P-29]小児インフルエンザA(H3N2)に対するバロキサビル治療とPA-I38T/M変異株が臨床経過に与える影響

*LINA YI¹, Narumi Matsuno^1,2, Reiko Saito^1,2, Japanese Influenza Collaborative Study Group³, Keita Wagatsuma¹, Tsutomu Tamura², Hisami Watanabe² (1. Division of International Health,Graduate School of Medical and Dental Sciences, 2. Infectious Diseases Research Center of Niigata University in Myanmar, 3. Japanese Influenza Collaborative Study Group)

[P-30]ナノポアシーケンサーを用いたインフルエンザウイルスゲノム解析手法の検討

*Ryohei Nomoto¹, Akeno Tokunaga¹, Rieko Kaji¹, Yuki Taira¹, Ai Mori¹ (1. KIH)

[P-31]Association of Influenza and COVID-19 Vaccination Status With 7C Model-Based Psychological Determinants Among Outpatients

*Moe Kuroda¹, Maiko Kuroiwa¹, Kaku Kuroda¹, Mayuko Saito¹, Yukihiro Sato², Kota Kawai^2,3, Taishi Ogawa^4,5, Hikaru Nozaki⁶, Kento Takeshima⁷, Keiichiro Kita^1,8, Makoto Kaneko⁹, Shota Kuroiwa¹, Masahisa Arahata^4,5, Akiteru Takamura^1,7 (1. Department of General Medicine, Toyama University Hospital, 2. Kamiichi General Hospital, 3. Kamiichi Community Medical Support Unit, Toyama University Hospital, 4. Nanto Community Medical Support Unit, Toyama University Hospital, 5. Nanto Municipal Hospital, 6. School of Medicine, Department of Medicine, University of Toyama, 7. Department of Medical Education / Center for Medical Education and Career Development, University of Toyama, 8. Fujikoshi Hospital, 9. Primary Care Research Unit, Department of Health Data Science, Yokohama City)

[P-32]医療従事者における新型コロナワクチンとインフルエンザワクチンの接種行動の乖離に関連する心理的背景

*Yo Murata^1,2, Meiwa Shibata^1,2,3, Hanako Funakoshi^1,2, Yuho Horikoshi^1,2 (1. Division of Infectious Diseases, Department of Pediatrics, Tokyo Metropolitan Children’s Medical Center, 2. Center for Pediatric Infectious Diseases, Tokyo Metropolitan Children’s Medical Center, 3. Division of Laboratory, Tokyo Metropolitan Children’s Medical Center)

[P-33]精神科閉鎖病棟における新型コロナウイルス集団感染事例の5年間の追跡から見たワクチンの役割と限界

*Hajime Kusuhara¹, Shinji Nakase², Shinichi Kanehara², Hitoshi Kanehara², Tomoyuki Uno³, Yasuyuki Hara³, Kiyosu Taniguchi⁴, Katsuhiro Komase⁵, Hajime Kamiya^5,6 (1. Mie Prefecture Health and Environment Research Institute, 2. Suzuka Kosei Hospital, 3. Department of Medical Health, Mie Prefecture, 4. NHO Mie National Hospital, 5. JIHS Center for Surveillance, Immunization, and Epidemiologic Research, National Institute of Infectious Diseases, 6. Department of Public Health, Occupational Medicine, and Applied Epidemiology, Mie University Graduate School of Medicine)

[P-34]日本における乳児のRSウイルス感染症予防戦略の費用対効果

*kazumasa kamei¹, Yoko Hirano¹, Yoshikazu Nakayama¹, Amy W Law² (1. Pfizer Japan Inc., 2. Pfizer Inc.)

[P-35]ヒトパピローマウイルス（HPV）ワクチン積極的勧奨の再開後における接種状況の分析（2022〜2024年度）

*Kaori Tanaka¹, Norihisa Yamamoto¹, Toshie Yoshida¹, Mai Okuyama¹, Saeko Morino¹, Takashi Ono¹, Ayu Kasamatsu², Masaki Ochiai³, Motoi Suzuki², Sayaka Takanashi¹ (1. Department of Immunization Research, National Institute of Infectious Diseases, Japan Institute for Health Security, Japan, 2. Center for Infectious Disease Epidemiology, National Institute of Infectious Diseases, Japan Institute for Health Security, Japan, 3. Center for Quality Management Systems, National Institute of Infectious Diseases, Japan Institute for Health Security, Japan)

[P-36]キャッチアップ接種世代に対するHPVワクチン接種状況把握のためのインターネット調査

*Asami Yagi¹, Motoko Kanno¹, Nobuhiko Suszuki¹, Shinichiro Takeda¹, Sayaka Ikeda¹, Yutaka Ueda¹ (1. 1)Department of Advanced Prevention and Health Sciences, Wakayama Medical University)

[P-37]愛知県における高校生を中心とした麻しん集団発生の疫学調査とウイルス遺伝子解析

*Yuho Yamada¹, Masaki Sassa¹, Emi Hirose¹, Yoshihiro Yasui¹ (1. Aichi Prefectural Institute of Public Health)

[P-38]関西圏在住の成人集団を対象とした麻疹・風疹・ムンプス抗体価調査

*Kotaro ISHIDA^1,2, Kaoru YAMANO^1,2, Naoya SHIRAISHI^1,2, Mitsuyo KOSAKA^1,2, Shiro TAKEKAWA², Hirotaka EBINA^1,2 (1. Virus Vaccine Group, BIKEN Innovative Vaccine Research Alliance Laboratories, Institute for Open and Transdisciplinary Research Initiatives, 2. The Research Foundation for Microbial Diseases of Osaka University)

[P-39]薬学部新入生の水痘及びムンプスワクチン接種状況と抗体価

*Yumiko Komori¹ (1. Faculty of Pharmacy, Meijo University)

[P-40]定期予防接種の累積接種率と新型コロナウイルス感染症の流行、および日本脳炎ワクチン、MRワクチン供給不足が接種率に与えた影響

*Hiroshi Sakiyama¹, Motoi Suzuki², Sayaka Takanashi² (1. Sakiyama Pediatric Clinic, 2. Japan Institute for Health Security, National Institute of Infectious Diseases, Center for Surveillance, Immunization, and Epidemiologic Research)

[P-41]地域住民向け帯状疱疹ワクチン普及啓発コンテンツのメッセージ設計とその理論的背景

*Masaki Machida^1,2, Hiroyuki Kikuchi^1,3, Tsuyoshi Okuhara⁴, Hiroyuki Mizuta¹, Mamoru Yanagimachi^5,6, Masataka Taguri⁷, Kazushige Ide⁸, Ken Ohyama⁹, Sawako Sawa¹⁰, Hikaru Sawada¹⁰, Shigeru Inoue¹ (1. Tokyo Medical University, Department of Preventive Medicine and Public Health, 2. Tokyo Medical University Hospital, Department of Infection Prevention and Control, 3. Public Health Research Foundation, Institute for Scientific Research of Stress , 4. The University of Tokyo, Department of Health Communication, , 5. Tokyo Medical University, Department of Molecular Pathology, 6. MEDEMIL Inc., 7. Tokyo Medical University, Department of Health Data Science, 8. Chiba University, Center for Preventive Medical Sciences, 9. Isen Town Office Health Promotion Section, 10. Isen Town Office Health Promotion Section Health Center)

[P-42]エンテロウイルス及びライノウイルスの疫学的動向に関する研究；2019～ 2024 年

*Youhei Tominaga¹, Yukie Inoue², Ryu Sumika³, Eisuke Tokuoka¹, Kazuhiro Horiba⁵, Masanori Hashino⁵, Miki Ogi⁴, Tsuguto Fujimoto⁵ (1. Department of Microbiology, Kumamoto Prefectural Institute of Public Health and Environmental Science, 2. Department of Health, Welfare and the Environment, Kamimashiki Area Development Bureau, Central Kumamoto Administrative Headquarters, Kumamoto Prefectural Government, 3. Public Sanitation and Pharmaceutical Division, Health Bureau, Department of Health and Welfare, Kumamoto Prefectural Government, 4. Hyogo Prefectural Institute of Public Health Science, 5. National Institute of Infectious Diseases, Japan Institute for Health Security)

[P-43]コクサッキーウイルスA2型、A4型、A6型の流行動態と組換え解析

*Miki Ogi¹, Tomohiro Oshibe¹, Tsuguto Fujimoto² (1. Infectious Disease Research Division, Hyogo Prefectural Institute of Public Health Science, 2. Department of Fungal Infection, National Institute of Infectious Diseases, Japan Institute for Health Security)

[P-44]新潟県における新生児・早期乳児発熱児に関連したエコーウイルス18型の流行

*Yuko Suzuki¹, Yuta Aizawa¹, Jun Tachikawa¹, Rie Habuka¹, Yuko Saito¹, Kanako Watanabe², Akihiko Saitoh¹ (1. Department of Pediatrics, Niigata University Graduate School of Medicine Dentistry and Health Sciences, 2. Department of Medical Technology and Science, Niigata University Graduate School of Medicine Dentistry and Health Sciences)

[P-45]蛍光マルチプレックスRT-PCR法の改良及び小児胃腸炎患者から検出された下痢症ウイルスの検出状況

*Mana Suei¹, Ayano Ito¹, Madoka Suzuto¹, Akie Nakashima¹, Naoki Shigemoto¹ (1. Public Health and Environment Center, Hiroshima Prefectural Institute of Technology Reseach)

[P-46]Temporal genetic changes in human bocavirus 1 in Fukushima, Japan, from 2018–2024

Tatsuya Shirai^2,1, Miyuki Kawase¹, Satoko Sugimoto¹, Masatoshi Kakizaki¹, Takashi Okura¹, Yohei Kume³, Hisao Okabe³, Sakurako Norito³, Hiroko Sakuma⁴, Shigeo Suzuki⁵, Hayato Go³, Mitsuaki Hosoya³, Koichi Hashimoto³, *Kazuya Shirato¹ (1. Japan Institute for Health Security, 2. Kyorin University, 3. Fukushima Medical University, 4. Hoshi General Hospital, 5. Ohara General Hospital)

[P-47]重症熱性血小板減少症候群ウイルスのアンプリコンシーケンス解析法の構築と分子疫学解析への応用

*Masaki Sassa¹, Emi Hirose¹, Yoshihiro Yasui¹ (1. Aichi Prefectural Institute of Public Health)

[P-48]第1期破傷風トキソイド含有ワクチン接種後の抗体保有状況調査

*Ai Hayashi^1,6, Karen Yamada¹, Kensuke Shoji², Naruo Saito³, Hideo Okuno⁴, Akinori Sugaya⁵, Miho Shibamura¹, Daichi Suzuki², Michimasa Fujiogi², Yuki Yamamoto², Noriko Kitamura¹, Sayaka Takanashi¹, Satoru Arai¹, Motoi Suzuki^1,6, Study Group (1. National Institute of Infectious Diseases, Japan Institute for Health Security, 2. National Center for Child Health and Development, 3. Saito Clinic for Asthma and allergy Chlidren, 4. Osaka City General Hospital, 5. Sugaya Children Clinic, 6. Tohoku University Graduate School of Medicine)

[P-49]Apical-Out Airway Organoidを用いた呼吸器ウイルス感染評価とハイスループットスクリーニング系への応用

*Masatoshi Kakizaki¹, Satoko Sugimoto^1,2, Miyuki Kawase¹, Koichi Hashimoto³, Kazuya Shirato¹ (1. Department of Respiratory Viruses, National Institute of Infectious Diseases, Japan Institute for Health Security, 2. Research Center for Biosafety, Laboratory Animal and Pathogen Bank, National Institute of Infectious Diseases,, 3. Department of Pediatrics, School of Medicine, Fukushima Medical University,)

[P-50]インフルエンザ感染マウスにおけるEAGLアッセイの確立と粘膜免疫評価への応用

*Yuriko TOMITA¹, Kaori Sano¹, Taro Saito², Hideki Hasegawa¹, Kei Miyakawa¹ (1. Japan Institute of Health and Security, National Institute of Infectious Disease, Influenza Research Center, 2. Canon Medical Diagnostics Corp. R&D Div.)

[P-51]糖鎖修飾の異なるインフルエンザワクチンにより誘導される免疫応答の解析

*Kayoko Sato¹, Noriko Shimasaki², Yueuke Nakai^2,3,4, Ryuichi Sugiyama², Mina Nakauchi², Kazuya Nakamura², Takahashi Hitoshi² (1. Department of Respiratory Viruses, National Institute of Infectious Diseases, Japan Institute for Health Security, , 2. Influenza Research Center, National Institute of Infectious Diseases, Japan Institute for Health Security, , 3. Department of Diagnostic Testing and Technology Research, National Institute of Infectious Diseases, Japan Institute for Health Security, 4. Department of Bioinformatics and Integrative Omics, National Institute of Infectious Diseases, Japan Institute for Health Security)

[P-52]Trivalent M2SR Intranasal Vaccine Provides Greater Mucosal Immunity than an Inactivated Influenza Vaccine in a Preclinical Model

*Shiho Chiba^1,2,3, Maki Kiso², Paul Radspinner⁴, Renee Herber⁴, Pamuk Bilsel⁴, Yoshihiro Kawaoka^1,2,3,5 (1. National Institute of Global Health and Medicine, Japan Institute for Health Security, 2. Pandemic Preparedness, Infection and Advanced Research Center, the University of Tokyo (UTOPIA), 3. The University of Wisconsin-Madison, 4. FluGen Inc, 5. Division of Virology, Institute of Medical Science, University of Tokyo)

[P-53]SARS-CoV-2オミクロン株に対する各種ブースターワクチンの免疫原性の検討

*Yohei Seki¹, Kiyoko Nojima¹, Sayuri Sakuragi¹, Haruka Momose¹, Shutoku Matsuyama², Ryoichi Sato³, Yasuo Yoshihara³, Takuo Mizukami¹ (1. Center for Next-Generation Biologics Research, National Institute of Infectious Diseases, Japan Institute for Health Security, 2. Department of Respiratory Viruses, National Institute of Infectious Diseases, Japan Institute for Health Security, 3. National Hospital Organization Murayama Medical Center)

[P-54]Development of a Comprehensive Profiling Serum Antibody Target Distribution Against SARS-CoV-2 Antigens

*Sho Miyamoto^1,2, Koki Numakura^2,3, Azumi Tamura⁴, Kotaro Kiga⁴, Haruko Takeyama³, Tadaki Suzuki^1,2 (1. Department of Infectious Disease Pathobiology, Chiba University, 2. Department of Infectious Disease Pathology National Institute of Infectious Diseases Japanese Institute for Health Security, 3. Graduate School of Advanced Science and Engineering, Waseda University, 4. Department of Drug Development, National Institute of Infectious Diseases, Japan Institute for Health Security)

[P-55]COVID-19 mRNAワクチン接種者およびウイルス感染回復者において誘導される抗体応答の特性の違い

*Shintaro Oishi^1,2, Ryutaro Kotaki^1,3, Hisham M Dokainish¹, Saya Moriyama¹, Shinichiro Ota⁴, Takayuki Matsumura¹, Tomohiro Takano¹, Taishi Onodera¹, Yu Adachi¹, Kazutaka Terahara¹, Masanori Isogawa⁵, Kazuhiko Katayama², Takashi Sato⁶, Masaharu Shinkai⁴, Yoshimasa Takahashi¹ (1. Research Center for Vaccine Development, National Institute of Infectious Diseases, Japan Institute for Health Security, 2. Laboratory of Viral Infection Control, Department of Infection Control and Immunology, Ōmura Satoshi Memorial Institute & Graduate School of Infection Control Sciences, Kitasato University, 3. Department of Molecular Systems Immunology, University of Tokyo Pandemic Preparedness, Infection, and Advanced Research Center (UTOPIA), 4. Respiratory Disease Center, Tokyo Shinagawa Hospital, 5. Department of Virology II, National Institute of Infectious Diseases, Japan Institute for Health Security, 6. Institute for Aqua Regeneration, Shinshu University, Nagano)

[P-56]タンデムエピトープ抗原を用いた新規CTL誘導型ユニバーサルSARS-CoV-2ワクチンの開発

*Yuji Masuta¹, Shokichi Takahama¹, Rigel Suzuki², Takuto Nogimori¹, Masayuki Aboshi³, Daisuke Kawakami³, Kaoru Kono³, Takahiro Tone³, Nakata Misako³, Takashi Sekida³, Wataru Akahata³, Takasuke Fukuhara², Takuya Yamamoto^1,4,5 (1. National Institutes of Biomedical Innovation, Health and Nutrition, 2. Faculty of Medical Sciences, Kyushu Univ., 3. VLP Therapeutics Japan, Inc., 4. Graduate School of Pharmaceutical Sciences, Osaka Univ., 5. Graduate School of Medicine, Osaka Univ.)

[P-57]遺伝子発現変動に基づくSARS-CoV-2ワクチンのモダリティ別反応原性の評価とin vitro評価法の検討

*Kou Hiraga¹, Haruka Momose¹, Mieko Ishii¹, Keiko Imai¹, Junichi Maeyama¹, Kazumi Nakano¹, Yohei Seki¹, Madoka Kuramitsu¹, Takuo Mizukami¹ (1. Center for Next-Generation Biologics Research, National Institute of Infectious Diseases, Japan Institute for Health Security)

[P-58]レーザーアジュバントのSタンパクワクチンにおける免疫応答への影響：MF59併用条件での検討

*Yuto Mano¹, Yohei Maki¹, Tomoya Sano¹, Takunori Ogawa¹, Toshihiro Kushibiki², Takeshi Ono³, Etsuko Kitagami¹, Kei Mikita³, Miya Ishihara², Yoshifumi Kimizuka¹ (1. Division of Infectious Diseases and Respiratory Medicine, Department of Internal Medicine, National Defense Medical College, 2. Department of Medical Engineering, National Defense Medical College, 3. Department of Global Infectious Diseases and Tropical Medicine, National Defense Medical College)

[P-59]マウスを用いた弱毒ワクシニアウイルスDIsのmpoxに対する有効性の解析

*Kenichi Otaki¹, Fumihiro Yasui², Youko Ishii¹, Naoko Kitagawa¹, Hirohito Ishigaki¹, Koji Ishii³, Michinori Kohara², Yasushi Itoh¹ (1. Division of Pathogenesis and Disease Regulation, Department of Pathology, Shiga University of Medical Science, 2. Department of Microbiology and Cell Biology, Tokyo Metropolitan Institute of Medical Science, 3. Department of Quality Assurance and Radiological Protection, National Institute of Infectious Diseases)

[P-60]百日咳菌外膜小胞を利用した経鼻百日咳ワクチンで誘導された抗体応答の持続性

*Kei Asayama^1,2, Rena Sakamoto^1,2, Itsuki Koyama^1,2, Ryouma Nakao³, Koji Tamura², Tadaki Suzuki¹, Akira Ainai¹ (1. Department of Infectious Disease Pathology, National Institute of Infectious Diseases, Japan Institute of Health Security, 2. Department of Biological Science and Technology, Faculty of Advanced Engineering, Tokyo University of Science, 3. Department of Bacteriology I National Institute of Infectious Diseases, Japan Institute of Health Security)

[P-61]Heterologous Route Prime–Boost Strategy Using Outer Membrane Vesicle-Based Vaccine

*Ryoma Nakao¹, Hiroki Uchiyama², Takehiro Yamaguchi¹, Kimihiro Abe¹, Aoi Takahashi¹, Manami Kimijima¹, Eisuke Kuroda³, Shigeto Hamaguchi⁴, Toshifumi Kudo⁵, Yukihiro Akeda¹ (1. Dept Bacteriol I, Natl Inst Infect Dis, JIHS, 2. Grad Sch Med, Science Tokyo , 3. Grad Sch Med, Nagoya Univ., 4. Osaka Inst Public Health, 5. Tsuchiura Kyodo General Hosp)

[P-62]肺炎球菌およびウェルシュ菌に対する多価ワクチンにおけるAlcaligenes Lipid A の舌下アジュバントとしての免疫学的機能と感染防御効果の検証

*Yuki Hirayama^1,2, Ken Yoshii¹, Atsushi Shimoyama^3,4, Keigo Iemitsu^1,5, Hiroshi Kiyono^6,7,8, Masuo Kondoh², Koichi Fukase^3,4, Jun Kunisawa^1,2,3,5,9,10 (1. Laboratory of Vaccine Materials and Laboratory of Gut Environmental System, Microbial Research Center for Health and Medicine, National Institutes of Biomedical Innovation, Health, and Nutrition, 2. Graduate School of Pharmaceutical Sciences, The University of Osaka, 3. Graduate School of Science, The University of Osaka, 4. Institute for Radiation Sciences, The University of Osaka, 5. Graduate School of Medicine, The University of Osaka, 6. Synergy Institute for Futuristic Mucosal Vaccine Research and Development (cSIMVa), Chiba University, 7. Department of Human Mucosal Vaccinology, Chiba University Hospital, Chiba, Japan, 8. Future Medicine Education and Research Organization, Chiba University, 9. Division of Adjuvant Innovation, International Vaccine Design Center, The Institute of Medical Science, The University of Tokyo, 10. Graduate School of Dentistry, The University of Osaka, Osaka, Japan)

[P-63]A bivalent vaccine for porcine epidemic diarrhea (PED)

*Qiang Liu¹, Shreya Sharma¹ (1. VIDO, University of Saskatchewan)

[P-64]経鼻ワクチンの有効性評価に利用可能なマウス分泌型IgA抗体測定系の確立

*Kaori Sano^1,2, Emi Hayashi³, Etsuko Yoshimi³, Taro Tachibana^3,4, Hideki Hasegawa^1,2, Kei Miyakawa^1,2 (1. Japan Institute for Health Security, National Institute of Infectious Diseases, Influenza Research Center, 2. Hokkaido University, Institute for Vaccine Research and Development, 3. Cell Engineering Corporation, 4. Osaka Metropolitan University, Graduate School of Engineering,)

[P-65]ヒアルロン酸ナノゲルを用いた安全な新規ワクチン開発

*Yuko Nariai¹, Toru Katsumata^1,2, Hiroki Kamino¹, Mya Myat Ngwe Tun^1,3, Shogo Aso², Kohei Yabuuchi², Fumiyasu Momose⁴, Yoshihiro Miyahara⁴, Tsuyoshi Shimoboji², Kazunari Akiyoshi⁵, Takeshi Urano⁵ (1. Center for Vaccines and Therapeutic Antibodies for Emerging Infectious Diseases, Shimane University, 2. Healthcare Materials Department, Asahi Kasei Corporation, 3. Institute of Tropical medicine, Nagasaki University, 4. Graduate School of Medicine, Mie University, 5. Graduate School of Medicine, Kyoto University)

[P-66]antiefinはmRNA-LNPワクチン誘発性炎症を抑制する新規脂肪酸である

*Keigo Iemitsu^1,2, Masashi Hotta¹, Yutaro Saito³, Ken Yoshii¹, Yuki Hirayama^1,4, Mengqi Wang^1,2, Shinsuke Sando^3,5, Jun Kunisawa^{1,2,4,6,7,8,9,10} (1. Laboratory of Vaccine Materials and Laboratory of Gut Environmental System, Microbial Research Center for Health and Medicine, National Institutes of Biomedical Innovation, Health, and Nutrition, 2. Graduate School of Medicine, The University of Osaka, 3. Department of Chemistry and Biotechnology, Graduate School of Engineering, The University of Tokyo, 4. Graduate School of Pharmaceutical Sciences, The University of Osaka, 5. Department of Bioengineering, Graduate School of Engineering, The University of Tokyo, 6. Graduate School of Science, The University of Osaka, 7. The Institute of Medical Science, The University of Tokyo, 8. Graduate School of Medicine, Kobe University, 9. Research Organization for Nano and Life Innovation, Waseda University, 10. Graduate School of Dentistry, The University of Osaka)

[P-67]1270 nm近赤外レーザーアジュバントのヒトケラチノサイトにおける生理活性の検討

*Ririko Shinozaki¹, Maki Youhei¹, Tomoya Sano¹, Takunori Ogawa¹, Toshihiro Kushibiki², Takeshi Ono³, Etsuko Kitagami¹, Kei Mikita³, Miya Ishihara², Yoshihumi Kimidsuka¹ (1. Division of Infectious Diseases and Respiratory Medicine, Department of Internal Medicine, National Defense Medical College, 2. Department of Medical Engineering, National Defense Medical College, 3. Department of Global Infectious Diseases, National Defense Medical College)

[P-68]連続波1064 nm近赤外光による粘膜ワクチンアジュバント作用における上皮細胞応答の検討

*Tomoya Sano¹, Yohei Maki¹, Yuto Mano¹, Ririko Shinozaki¹, Takunori Ogawa¹, Toshihiro Kushibiki², Takeshi Ono³, Etsuko Kitagami¹, Kei Mikita³, Miya Ishihara², Yoshifumi Kimizuka¹ (1. Division of Infectious Diseases and Respiratory Medicine, Department of Internal Medicine, National Defense Medical College, 2. Department of Medical Engineering, National Defense Medical College, 3. Department of Global Infectious Diseases and Tropical Medicine, National Defense Medical College)

Cancelled

[P-69]演題取り下げ

[P-70]IdeS improves vaccination efficacy and gene delivery by reducing pre-existing antibodies

*Yuzy Fauzyah^1,2, Paola Miyazato^1,2, Kotaro Ishida^1,2, Shinya Okamura^1,2, Hirotaka Ebina^1,2,3,4,5 (1. The Research Foundation for Microbial Diseases of Osaka University (BIKEN), Suita, Osaka, Japan, 2. Virus Vaccine Group, BIKEN Innovative Vaccine Research Alliance Laboratories, Institute for Open and Transdisciplinary Research Initiatives, The University of Osaka, Suita, Osaka, Japan, 3. Research Institute for Microbial Diseases, The University of Osaka, Suita, Osaka, Japan, 4. Center for Advanced Modalities and DDS (CAMaD), The University of Osaka, Suita, Osaka, Japan, 5. Center for Infectious Disease Education and Research (CiDER), The University of Osaka, Suita, Osaka, Japan)

[P-71]mRNA-LNP接種部位における空間トランスクリプトーム解析

*Tomohiro Takano¹, Takayuki Matsumura¹, Yoshimasa Takahashi¹ (1. Research Center for Vaccine Development, National Institute of Infectious Diseases, Japan Institute for Health Security)

[P-72]鳥インフルエンザH5N1 mRNAワクチン開発のためのin vitro力価試験の構築と評価

*Yuko Misumi^1,2, Masayo Kanayama¹, Tomoko Satomi¹, Reika Shiratori¹, Tomohiro Narahara¹, Taku Morishita¹, Takashi Matsuzaki³, Satoshi Abe¹, Kuzuyuki Nakashima¹ (1. ARCALIS, Inc., 2. Axcelead Drug Discovery Partners, Inc., 3. Department of DDS Pharmaceutical Development, Graduate School of Medicine, The University of Osaka)

[P-73]Clade2.3.2.1aに属する新規H5N1亜型インフルエンザワクチン候補株の開発

*Yasushi Suzuki¹, Tomoko Arita¹, Eita Sasaki¹, Masayuki Shirakura¹, Noriko Kishida¹, Kaori Sano¹, Shinj Watanabe¹, Naoko Iwata², Yusuke Sakai², Nozomi Shiwa², Noriyo Nagata², Tadaki Suzuki², Hideki Hasegawa¹, Hideki Asanuma¹ (1. Japan Institute for Health Security, National Institute of Infectious Diseases, Influenza Research Center, 2. Japan Institute for Health Security, National Institute of Infectious Diseases, Department of Infectious Disease Pathology)

[P-74]細胞培養インフルエンザワクチン製造における抗原液収量改善へのマイクロキャリアビーズ培養法の有用性評価検討

*Kazuya Nakamura¹, Shoya Hiratoko², Mina Nakauchi¹, Youngjin Kim², Yusuke Nezu², Hideki Hasegawa¹, Toshifumi Mogami², Hitoshi Takahashi¹ (1. National Institute of Infectious Diseases, Japan Institute for Health Security, 2. TOSOH Co.)

[P-75]Expi293F細胞由来組換えHAタンパク質のパンデミックインフルエンザワクチン力価試験用抗原としての適用可能性の検討

*Ryuichi Sugiyama¹, Noriko Shimasaki¹, Lui Sze Wai¹, Keiko Murano¹, Takiko Yoshida¹, Kayoko Sato², Toru Takenaga^1,3, Yusuke Nakai^1,3,4, Yuichi Harada¹, Shigeyuki Itamura¹, Hideki Hasegawa¹, Akihide Ryo⁴ (1. Influenza Research Center, National Institute of Infectious Diseases, JIHS, 2. Department of Respiratory Viruses, National Institute of Infectious Diseases, JIHS, 3. Department of Diagnostic Testing and Technology Research, National Institute of Infectious Diseases, JIHS, 4. Department of Bioinformatics and Integrative Omics, National Institute of Infectious Diseases, JIHS)

[P-76]インフルエンザHAを対象としたID-MS標的ペプチド選定パイプラインの構築と機械学習による測定適性向上の試み

*Toru Takenaga^1,2, Ryuichi SUGIYAMA², Yusuke NAKAI^1,2,3, Yuichi HARADA², Noriko SHIMASAKI², Hideki HASEGAWA², Akihide RYO³ (1. Japan Institute for Health Security (JIHS) National Institute of Infectious Diseases (NIID) Department of Diagnostic Testing and Technology Research, 2. Japan Institute for Health Security (JIHS) National Institute of Infectious Diseases (NIID) Influenza Research Center, 3. Japan Institute for Health Security (JIHS) National Institute of Infectious Diseases (NIID) Department of Bioinformatics and Integrative Omics)

[P-77]2026-2027年シーズンの国内インフルエンザワクチン候補株の解析

*Hideki Asanuma¹, Tomoko Arita¹, Yasushi Suzuki¹, Eita Sasaki¹, Yuichi Harada¹, Shinji Watanabe¹, Noriko Kishida¹, Seiichiro Fujisaki¹, Kazuya Nakamura¹, Hitoshi Takahashi¹, Hideki Hasegawa¹ (1. Japan Institute for Health Security)

[P-78]新型コロナウイルスNB.1.8,1、XFGのJN.1系統およびBA.3.2系統のSタンパク質をコードする自己増幅型mRNA-LNPワクチンのマウス免疫原性評価

*Akihito Sawada¹, Eisuke Suzuki¹, Yuusuke Okada¹, Meagan Mcmahon², Angela Nguyen², Trang T Nguyen², Xiang Huang², Nicole Bisset², Nedzad Music³, Karen Louise Laurie² (1. Meiji Seika Pharma Co., Ltd., 2. CSL Seqirus, Melbourne, 3. CSL Seqirus, Waltham)

[P-79]改変一価スパイクタンパク質ワクチンS‑567123のサルベコウイルスに対する広域なワクチン効果の発揮

*Takayuki Nakagawa¹, Naomi M Seki¹, Saya Moriyama², Tsujii Kenichiro¹, Keiji Dohi¹, Yimei Wang², Masaaki Sato¹, Takeshi Ota¹, Yusuke Sako¹, Yoshiji Asaoka¹, Po-Hung Wang³, Yoshimasa Takahashi², Kazuo Yamashita³, Mina Yamamoto¹, Isamu Nanchi¹ (1. SHIONOGI & CO., LTD., 2. National Institute of Infectious Diseases, Japan Institute for Health Security, 3. KOTAI Biotechnologies, Inc.)

[P-80]ジフテリア・破傷風・百日咳（DPT）抗原に対するヒトおよびマウス血清IgG抗体測定用4項目同時測定免疫測定法の開発と検証

*yuko Nakatsu¹, Kohsuke Kumeda^1,2, Chiyomi Sakamoto^3,2, Chie Shitada^3,2, Takanori Matsuo¹, Susumu Yamaori¹, Motohide Takahashi^2,3 (1. KM Biologics Co.,Ltd, 2. Kumamoto Health Science University, 3. Therapeutic Research Institute)

[P-81]ジフテリア抗体価測定ELISAの確立とDPT-IPVワクチン力価試験代替法への応用

*Takanori Matsuo¹, Kohsuke Kumeda^1,2, Chiyomi Sakamoto^2,3, Chie Shitada^2,3, Susumu Yamaori¹, Motohide Takahashi^2,3 (1. KMBiologics Co., Ltd., 2. Kumamoto Health Science University, 3. The Chemo-Sero-Therapeutic Research Institute (KAKETSUKEN))

[P-82]破傷風トキソイド品質管理におけるGanglioside Binding Assayの開発

*Susumu Yamaori¹, Yuki Tanoue^3,2, Chie Shitada^2,3, Mariko Nakamichi¹, Naomi Nakamichi¹, Chiyomi Sakamoto^2,3, Hyun Kim⁴, Kosuke Kumeda¹, Masaki Ochiai⁴, Mitsutoshi Senoh⁴, Motohide Takahashi^2,3 (1. KM Biologics Co., Ltd., 2. Kumamoto Health Science University, 3. The Chemo-Sero-Therapeutic Research Institute, 4. Japan Institute for Health Security, National Institute of Infectious Diseases)

[P-83]大豆ペプトンによる動物由来成分不使用培地化で髄膜炎菌の増殖と多糖抗原収率を改善

*Kentaro Kuroki¹, Elizabeth O’Hanlon¹, Yarden Sorek¹, Stacy Holdread¹ (1. Thermo Fisher Scientific)

[P-84]本邦において承認されたワクチンの歴史的変遷

*Kao Hayata¹, Takashi Ogawa¹, Kenji Sawanobori¹, Tomonori Shiokawa¹ (1. Pharmaceuticals and Medical Devices Agency)

[P-85]Benefits of prefilled syringes for vaccine administration

*Mitsuru Takahashi¹, Takeaki Kawashima¹, kenjiro Nishihara¹ (1. Nippon Becton Dickinson Company, Ltd.)

[P-86]Assessment Materials and Deliberative Processes for Incorporating Voluntary Vaccines into Routine Immunization Programs: A Comparative Study of Nine Countries and Implications for Japan

*Megumi Hara¹, Haruhisa Fukuda² (1. Preventive Medicine, Saga University, 2. Department of Health Care Administration and Management, Graduate School of Medical Sciences, Kyushu University)

Session Details